← Encyclopedia

The FDA's formal rejection letter for a drug application, explaining what would need to change for approval.

Example: Lykos (now Resilient Pharmaceuticals) received one for its MDMA-PTSD therapy in August 2024, and has since quietly resubmitted without running a new Phase 3 trial — see where that stands.